MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that at an Analyst Day meeting to be held 11 a.m. to 2 p.m. on April 17 in New York City, the company will present an update of the pivotal Phase III ACAPODENE® clinical trials and information about its clinical development and commercialization plans for Ostarine™, its first-in-class selective androgen receptor modulator (SARM).
